Login| Sign Up| Help| Contact|

Patent Searching and Data


Title:
FUSION PROTEIN COMPRISING IDS AND USE THEREOF
Document Type and Number:
WIPO Patent Application WO/2020/085721
Kind Code:
A1
Abstract:
The present invention relates to an asymmetric fusion protein in which an antibody fragment binding to an insulin receptor, an IDS enzyme, and an Fc region are fused, and a use thereof. The fusion protein can cross the blood-brain barrier (BBB) to deliver the IDS enzyme to the brain. Therefore, a pharmaceutical composition comprising the fusion protein as an active ingredient can be used as a therapeutic agent for a central nervous system disease and particularly, is expected to prevent and treat various diseases caused by ribosome accumulation.

Inventors:
CHO KI JOON (KR)
LEE MIJUNG (KR)
SONG EUN JUNG (KR)
KIM KI SU (KR)
KANG KWAN YUB (KR)
CHO EUI CHEOL (KR)
Application Number:
PCT/KR2019/013730
Publication Date:
April 30, 2020
Filing Date:
October 18, 2019
Export Citation:
Click for automatic bibliography generation   Help
Assignee:
MOGAM INST BIOMEDICAL RES (KR)
International Classes:
C07K16/28; A61K38/46; A61K47/68; A61P25/00; C12N9/16
Domestic Patent References:
WO2018038243A12018-03-01
Foreign References:
US20180251535A12018-09-06
US20170226222A12017-08-10
US20160152719A12016-06-02
KR20130043165A2013-04-29
KR20160011198A2016-01-29
KR20150039798A2015-04-13
US4816567A1989-03-28
Other References:
RIDGWAY ET AL., PROTEIN ENGINEERING, 1996, pages 617 - 621
CLACKSON ET AL., NATURE, vol. 352, 1991, pages 624 - 628
KOHLERMILSTEIN, EUROPEAN JOURNAL OF IMMUNOLOGY, vol. 6, 1976, pages 511 - 519
See also references of EP 3875483A4
Attorney, Agent or Firm:
FIRSTLAW P.C. (KR)
Download PDF: